Peripheral location and infiltrative margin predict invasive features of papillary thyroid microcarcinoma

in European Journal of Endocrinology
Correspondence should be addressed to Y S Jo; Email: joys@yuhs.ac

*(W K Lee and J Lee contributed equally to this work)

Restricted access

Objective

Tumor location in papillary thyroid microcarcinoma (PTMC) might determine tumor outgrowth from the thyroid gland. However, the clinical implications of tumor location and minimal extrathyroid extension (mETE) have not been well elucidated. We aimed to investigate the relationship between tumor location and mETE to predict the aggressiveness of PTMC.

Methods

A total of 858 patients with PTMC were grouped according to tumor location on ultrasonography: central (cPTMC) and peripheral PTMC (pPTMC). PTMC without mETE (PTMC-mETE(−)) was divided further according to margin shape: encapsulated (E−) or infiltrative (I−). To understand the molecular biologic characteristics of PTMC presenting with an I-margin and mETE, transcriptome data from TCGA-THCA were analyzed using Gene Set Enrichment Analysis (GSEA).

Results

pPTMC (n = 807, 94.1%) accounted for the majority of cases; mETE was identified only in pPTMC (403/807; 49.9%). pPTMC-mETE(+) showed aggressive clinical characteristics that increased the odds ratio (OR) for lymph node metastasis (LNM). Interestingly, subgroup analysis of PTMC-mETE(−) revealed that the I-margin also increased the OR for LNM, independent of other clinical factors. GSEA of TCGA-THCA data suggested coordinated upregulation of genes related to epithelial-mesenchymal transition (EMT) in PTC with mETE. Immunohistochemical staining for laminin subunit gamma 2 (LAMC2), CD59, E-cadherin and vimentin showed that these markers of EMT were associated with progressive changes in E-margin PTMC-mETE(−), I-margin PTMC-mETE(−) and pPTMC-mETE(+).

Conclusion

mETE related to peripheral location of PTMC is an important predictor of tumor invasiveness, as is the I-margin, which presents with EMT features similar to mETE. I-margin PTMC-mETE(−) and pPTMC-mETE(+) might reflect the pattern of invasive PTMC.

Downloadable materials

  • Supplementary Table 1. Thyroid volume (mL) of patients in this study compared with that of patients in previous studies
  • Supplementary Table 2. Multivariable analysis to determine relationships between tumor location and clinico-pathological factors and LNM in PTMC.
  • Supplementary Table 3. Multivariable analysis to determine the association between minimal ETE and LNM in TCGA-THCA
  • Supplementary Table 4. Multivariable logistic regression model (adjusted for all clinicopathological parameters) to determine the association between minimal ETE and tumor recurrence in TCGA-THCA.
  • Supplementary Figure 1. Classification of ultrasonographic tumor location. (A and B) Representative ultrasonographic axial images of cPTMC (A) and pPTMC (B). Abbreviations: cPTMC, central papillary thyroid microcarcinoma; pPTMC, peripheral papillary thyroid microcarcinoma.
  • Supplementary Figure 2. Clinicopathological implications of mETE in TCGA-THCA. (A and B) Comparison of tumor size (A) and LNM (B) according to ETE status (two-tailed Student’s t test, one-way ANOVA, or Chi-squared test). (C) Kaplan-Meier survival analysis according to ETE status. Data in A represent the mean ± SD. Missing data were excluded from each analysis. ns = non-significant, * = P < 0.05, **** = P < 0.0001. Abbreviations: EMT, epithelial-mesenchymal transition; ETE, extrathyroidal extension; LNM, lymph node metastasis; DM, distant metastasis; THCA, Thyroid Cancer; mETE, minimal ETE; gETE, gross ETE.
  • Supplementary Figure 3. Clinico-pathological implications of mETE in PTMC from TCGA-THCA. (A) Gene set related to EMT was coordinately up-regulated in PTC with mETE. (B) Frequent LNM in PTC with mETE. (C–F) Comparison of tumor size (C), tumor recurrence (D), age (E), and gender ratio (F) according to the presence of mETE. Continuous data were compared using a two-tailed Student’s t test, and categorical data were compared using the Chi-squared or Fisher’s exact test. Data represent the mean ± SD. ns = non-significant, * = P < 0.05, ** = P < 0.01.
  • Supplementary Figure 4. Representative markers of EMT in TCGA-THCA. (A) Heatmaps indicating the candidate genes, LAMC2 and CD59, in PTC and PTMC TCGA-THCA. Asterisks indicate genes showing significant differences in expression according to the presence of minimal ETE. (B) Expression of mRNA encoding LAMC2 and CD59 in normal and PTC tissue. Error bars indicate the mean ± SD. Continuous variables were analyzed using a two-tailed Student’s t test. ns = non-significant, **** = P < 0.0001.

 

     European Society of Endocrinology

Related Articles

Article Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 214 214 166
Full Text Views 36 36 27
PDF Downloads 30 30 19

Altmetrics

Figures

  • View in gallery

    Clinical implications of the I-margin and minimal ETE in PTMC. (A) Representative hematoxylin and eosin (H&E) images of PTMCs with an E- and I-margin. (B) Comparison of LNM incidence according to the classification of PTMC (i.e., mETE, tumor location and margin shape; see manuscript text for details). Scale bars, 25 μm. ns, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. ETE, extrathyroidal extension; E-margin, encapsulated margin; I-margin, infiltrative margin; LNM, lymph node metastasis; PTMC, papillary thyroid microcarcinoma.

  • View in gallery

    LAMC2 and CD59 as EMT markers in PTC with ETE or LNM. (A and B) The results of GSEA of data from TCGA-THCA indicate coordinated upregulation of certain gene sets in PTC with mETE (A) and LNM (B). Important hallmark signaling pathways are highlighted in red (nominal P value <0.05; FDR q-value <0.25). (C) LAMC2 and CD59 expression according to ETE status. (D) LNM frequency according to LAMC2 and CD59 expression status. ns, non-significant, *P < 0.05, and ****P < 0.0001. CD59, CD59 molecule; EMT, epithelial-mesenchymal transition; gETE, gross ETE; GSEA, Gene Set Enrichment Analysis; LAMC2, laminin subunit gamma 2; mETE, minimal ETE; TCGA, The Cancer Genome Atlas; THCA, thyroid cancer.

  • View in gallery

    Representative IHC-P images showing expression of CDH1, VIM, LAMC2 and CD59 according to the classification system used herein. Images were obtained from the margin of tumors in each group. Scale bars, 100 μm. CDH1, cadherin 1, type 1, E-cadherin (epithelial); IHC-P, immunohistochemistry-paraffin; VIM, vimentin.

PubMed

Google Scholar